Lindermann, A., Brossart, P., Hoffken, K., et al. (1993) Immunomodulatory Effect of Ultra-Low-Dose Interleukin-2 in Cancer Patients: A Phase-1B Study. Cancer Immunotherapy, 37, 307.
https://doi.org/10.1007/BF01518453

has been cited by the following article:

• TITLE: Improving 21st Century Cancer Therapy: Correcting Treatment Paradoxes and Combining Integrative and Conventional Oncology

  AUTHORS: R. L. Elliott, X. P. Jiang, C. C. Baucom

  KEYWORDS: Cancer Immunotherapy, Lymphocyte Count, Gut Microbiome, Metabolic Therapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.11 No.11, November 23, 2020

  ABSTRACT: Recently there have been many advances in cancer treatment, however, treatment results would be much better if clinical oncologists were educated on the research of cancer metabolism and basic cancer immunology. Many medical oncologists have deficiency in these areas and are devoted to treatment protocols and totally against integrative oncology. One neglected problem is a lack of attention to the cancer patient’s host immunity, which should be evaluated at diagnosis. This huge barrier between integrative and conventional oncology should be eliminated for the benefit of the cancer patient. This communication is an attempt to resolve these important treatment details and bring awareness to this problem.